The World Health Organisation has authorised Novavax updated vaccine shots for active immunization to prevent COVID-19 in individuals aged 12 and older
Covid 19 pandemic swept the world with their style of living. With different waves of the virus hitting different regions at different times, people have become more health conscious. The fatal spread of the disease got the scientists working day and night to develop a vaccine. After different kinds of covid shots being rolled out, recently U.S. regulators recently authorized another option for fall COVID-19 vaccination, updated shots made by Novavax.
Novavax’s (NVAX.O) updated vaccine has been granted emergency-use authorization by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older, the company said on Tuesday.
Novavx Covid Vaccine Authorised For Emergency Use – 5 Points
- The updated Novavax shot, which was authorized in the U.S. last month, targets a descendant of the XBB lineage of the coronavirus that was globally predominant earlier this year.
- The emergency use listing helps speed up the regulatory approvals to import and administer the vaccines by member states, according to the WHO.
- Novavax missed out on the COVID-19 vaccine windfall, which benefited mRNA rivals, due to manufacturing issues that delayed its filing for regulatory approval during the peak of the pandemic.
- Its original Covid- shot received U.S. authorization in July 2022, long after Pfizer (PFE.N) and Moderna (MRNA.O) vaccines were in use.Novavax’s updated shot uses a more traditional protein-based technology than the mRNA-based vaccines by Pfizer and Moderna.
Protection against Covid-19, whether from vaccination or from an earlier infection, wanes over time. There’s already been a late-summer increase in infections, and health officials hope enough people get the new shots to blunt a winter wave.
(With agency inputs)